Bicara Therapeutics Inc Common Stock

Yahoo Finance • 19 days ago

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembroliz... Full story

Yahoo Finance • last month

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves

The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in... Full story

Yahoo Finance • 2 months ago

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC 

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that... Full story

Yahoo Finance • 2 months ago

Genmab reportedly nearing deal to acquire cancer drug developer Merus

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Danish biotech Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) is in advanced discussions to acquire Merus (NASDAQ:MRUS [https://seekingalpha.com... Full story

Yahoo Finance • 3 months ago

Bicara Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright lowers Bicara Therapeutics stock price target to $40 on expenses

Investing.com - H.C. Wainwright reduced its price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $40.00 from $41.00 on Friday, while maintaining a Buy rating on the stock. The $635 million market cap company has seen its shares decli... Full story

Yahoo Finance • 4 months ago

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-nega... Full story

Yahoo Finance • 5 months ago

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on... Full story

Yahoo Finance • 6 months ago

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 6 months ago

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that... Full story

Yahoo Finance • 6 months ago

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call a... Full story

Yahoo Finance • 6 months ago

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX). This follows the American Society of Clinical Oncology (ASCO) releasing abstracts after the market's close, whic... Full story

Yahoo Finance • 6 months ago

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment. Continue Reading View Comments... Full story

Yahoo Finance • 6 months ago

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the p... Full story

Yahoo Finance • 7 months ago

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approx... Full story

Yahoo Finance • 7 months ago

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced tha... Full story

Yahoo Finance • 8 months ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approxim... Full story

Yahoo Finance • 8 months ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced tha... Full story

Yahoo Finance • 9 months ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that... Full story

Yahoo Finance • 10 months ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the... Full story